Back to results
US 12,213,975 B2Granted
PDE9 inhibitors for treating sickle cell disease
AssigneeCardurion Pharmaceuticals, LLC
InventorsEdward George Calamai, Deborah Lynn Leithead Dobbins, Michael Paul Dehart, James McArthur, Shi Yin Foo
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to PDE9 inhibitors, pharmaceutical compositions comprising the PDE9 inhibitors, and methods of using the PDE9 pharmaceutical compositions for the treatment of sickle cell disease (SCD).
Claims7
An oral tablet composition, comprising:
- 50 mg 6-[(3S,4S)-4-methyl-1-(pyrimidin-2-ylmethyl) pyrrolidin-3-yl]-3-tetrahydropyran-4-yl-7H-imidazo[1,5-a]pyrazin-8-one (Compound 1),
- about 20%, about 30%, or about 40% by weight microcrystalline cellulose (MCC),
- about 1% by weight colloidal silicon dioxide, and
- about 0.8% by weight magnesium stearate.
1 more element
An oral tablet composition, comprising:
- 50 mg 6-[(3S,4S)-4-methyl-1-(pyrimidin-2-ylmethyl) pyrrolidin-3-yl]-3-tetrahydropyran-4-yl-7H-imidazo[1,5-a]pyrazin-8-one (Compound 1),
- about 20% or about 30% by weight microcrystalline cellulose (MCC),
- about 1% by weight colloidal silicon dioxide,
- about 0.8% by weight magnesium stearate, and
- one or more solid carriers comprising lactose.
2 more elements
Dependencies are inferred from the claim text.